Phenylketonuria: Prevalence and Inheritance

PKU (phenylketonuria) is a rare, inherited metabolic disorder in which the body is unable to break down the amino acid phenylalanine. This leads to a harmful accumulation of phenylalanine in the blood and brain. If left untreated, PKU causes severe intellectual disability and developmental disorders; however, it is detected early through newborn screening. Treatment consists of a lifelong, strictly low-protein diet to minimize phenylalanine intake and enable normal development.

Phenylketonuria (PKU) is inherited in an autosomal recessive manner.

  • The cause is a mutation in the PAH gene (phenylalanine hydroxylase gene) on chromosome 12.
  • For the disease to occur, both copies of the gene (one inherited from the mother and one from the father) must be mutated.
  • PKU is an autosomal recessive genetic disorder in which a child is affected only if it inherits two defective PAH genes. Unaffected parents may be carriers.

The diagram on the right shows a graphical inheritance scheme for phenylketonuria (PKU) with autosomal recessive inheritance, compared to the diagram on the left illustrating dominant inheritance. The most common and clinically most relevant scenario is when both parents are healthy carriers.

This image was created using artificial intelligence. .

  • A systematic review based on neonatal screening data reports a worldwide prevalence of approximately 6 cases per 100,000 newborns (i.e., about 1 in 16,600), with substantial regional variation (e.g., ranging from 0.3 to 38 per 100,000) due to genetic and socio-cultural factors. (PMC)
  • Other sources report a similar mean global incidence of approximately 1 case per 23,930 newborns worldwide. (lidsen.com)

Total Number of Affected Individuals Worldwide

  • A frequently cited epidemiological estimate assumes that approximately 0.45 million (450,000) people worldwide are living with PKU. (PMC)
  • Another estimate (from patient-based sources) suggests around 58,000 people with PKU worldwide; however, this figure is likely a significant underestimate and appears to be based primarily on registered or reported cases rather than epidemiologically supported data. (PTC Therapeutics (Germany))

Regional Differences (Summary)

  • Incidence varies markedly by geography, ranging from high rates (e.g., in parts of the Middle East, Turkey, Ireland, and Italy) to very low rates in many Asian and African populations. (PMC)
  • In Europe, prevalence is often approximately 1 in 8,000 to 1 in 10,000 newborns. (pharma-fakten.de)

Key Figures (Summary)

  • Global incidence in newborns: approximately 1 in 16,600 to 1 in 23,930 (or 5–6 per 100,000). (PMC)
  • Estimated total number of affected individuals worldwide: approximately 0.45 million people. (PMC)

Overview Table: Incidence of Phenylketonuria (PKU) in the United States by Ethnic Group

Ethnic Group

PKU Incidence (Newborns)

Source / Comment

Total U.S. population

Approx. 1 in 15,000 births

Standard figure from U.S. screening data. PKU is overall more common among Whites/Native Americans and less common in other groups. (NCBI)

White (Caucasian)

Approx. 1 in 10,000

Higher incidence in this ethnic group compared with the U.S. average. (Wikipedia)

Native Americans

≥ U.S. average (relatively increased)

Incidence above the U.S. average; specific rates vary by region. (NCBI)

Hispanic

< U.S. average

Lower incidence compared with Whites; no single uniform value published. (NCBI)

African American (Black)

< U.S. average

Significantly lower incidence than in Whites; screening data indicate reduced frequency. (NCBI)

Asian American / other Asian populations

< U.S. average

Relatively rare compared with Whites; no consistently published precise rates. (NCBI

Summarized Interpretation

  • The overall PKU incidence in the United States is approximately 1 case per 15,000 births. (NCBI)
  • White individuals show the highest incidence, at approximately 1 in 10,000 births. (Wikipedia)
  • Native Americans also have an increased rate compared with the U.S. average, whereas African American, Hispanic, and Asian American groups tend to exhibit lower incidence rates. (NCBI)